ASN: PPI Use May Up Risk for AKI After Cardiac Surgery
Adults receiving proton pump inhibitors have increased risk for acute kidney injury requiring dialysis following cardiac surgery
Diagnosis & Disease Information
Even Low Levels of Lead in Drinking Water May Harm ESKD Patients
Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
Acute Kidney Injury in Severe COVID-19 Cases Predicts Higher Death, Cardiovascular Risks
A study found no significant increased risks for death or major adverse cardiac events among infected patients with established chronic kidney disease or end-stage kidney disease.
Dapagliflozin Reduces Risk for Kidney Events in IgA Nephropathy
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
COVID-19 Virus Spike Protein Detected in Urine
In a small study, 25% of adults with COVID-19 shed SARS-CoV-2 spike S1 protein in their urine at least once during the course of infection.
Nicotinamide May Improve Phosphate Control in Hemodialysis Patients
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.
Terlipressin Bests Placebo in Type 1 Hepatorenal Syndrome
Terlipressin is more effective for reversal of HRS but is associated with more adverse events and death due to respiratory disorders
Conservative CKD-MBD Management at Dialysis Initiation on the Rise
Trends suggest that clinical practice could be driven heavily by providers’ preferences and beliefs, resulting in substantial practice variation.
Iron Replacement Therapy Triferic AVNU Now Available
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Sparsentan Granted Orphan Drug Status for IgA Nephropathy
Sparsentan is an investigational small molecule candidate designed to selectively block the receptors of endothelin type A and angiotensin II type I, which are associated with kidney disease progression.
